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Cyclodextrins are chemicals and 
physically stable macromolecules made by 
protein degradation of starch. They are water-
soluble, biocompatible in nature with 
hydrophilic outer surface and lipophilic 
cavity. (1) They have the shape of truncated 
cone or torus rather than perfect cylinder 
because of the chair conformation of 
glucopyranose unit. (2) The CDs of 
biomedical and pharmaceutical interest are 
cyclic oligosaccharides made up of six to 
eight dextrose units (α-, β-, and γ-CDs, 
respectively) joined through one to four 
bonds. The most common natural 
cyclodextrins are 𝛼, 𝛽, and 𝛾 consisting of 6, 
7, and 8 glucopyranose units. (3,4) The 
derivatives of 𝛽-cyclodextrin are listed in 
Table 1. 
“Cyclodextrin “molecules are large with a 
number of hydrogen donors. Cyclodextrins 
are widely used as "molecular cages" in the 
pharmaceutical, agrochemical, food and 
cosmetic industries. (5) In the pharmaceutical 
industry they are used as complexing agents 
to increase the aqueous solubility of poorly 
soluble drugs and to increase their 
bioavailability and stability. (6) Cyclodextrin 
consists of (α-1,4)-linked α-D-glucopyranose 
unit with a lipophilic central cavity and the 
structures of various CDs are as shown in 
Figure 1. The naturally occurring 
cyclodextrins have limited aqueous solubility 
due to the strong intermolecular hydrogen 
bonding in the crystal state. Substitution of 
the H-bond forming -OH group has improved 
their solubility. (7, 8)” 
Inclusion complexes are formed when the 
“guest” molecule usually a drug is partially or 
fully included inside the “host’s cavity” (9). 
The outer sphere of cyclodextrins is 
compatible with water, which allows 
hydrogen bonding cohesive interactions. (10-
12) Due to this feature, CDs form inclusion 
complexes with a wide variety of 
hydrophobic compounds and change the 
physicochemical and biological properties of 
guest molecules. (13) The ability of a CD to 
form an inclusion complex is a function of 
steric as well as thermodynamic factors. The 
driving force for complexation involves the 
removal of water molecule from hydrophobic 
cavity and formation of Vander Waal forces, 
hydrophobic, and hydrogen bond interactions. 
(14-16) The approach used for complexation 
is phase solubility study as described by 
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Higuchi and Connors, which examines the 
effect of cyclodextrin (solubilizer/ligand) on 
the drug being solubilized (substrate) and 
several examples of cyclodextrin enhanced 
solubility for various drugs are listed in Table 
2.  
Table1. Pharmaceutical derivatives of β-cyclodextrins 
Cyclodextrin R=H or 
Β-Cyclodextrin -H 
2-Hydroxypropyl-β-cyclodextrin -CH2CHOHCH3 





2,6 dimethylated-β-cyclodextrin -CH3 
Branched β-cyclodextrin Glucosyl or maltosyl group 
 
2. Cyclodextrin Complexation with 
Anticancer Drugs 
“Chemotherapy has limited therapeutic 
effect. Limited aqueous solubility 
(hydrophobicity), degradation in 
gastrointestinal fluids, insufficient in vitro 
stability (shelf life), low bioavailability, short 
in vivo stability (half-life), affinity for 
intestinal and liver cytochrome P450 
(CYP3A4) and Pglycoprotein (P-gp) in the 
intestinal barrier, poor intestinal 
permeabilities, and strong dose dependent 
side effects of promising anticancer drug 
candidates have long been obstacles in 
treatment of cancer. (17,18) Lack of 
selectivity and short blood circulation time 
which cause various toxic side effects are also 
issues of major concern. (19) The narrow 
therapeutic index of some anticancer drugs 
and the fact that these cytotoxic drugs 
damage not only cancer cells but also normal 
and healthy tissue is a major challenge. 
Multidrug resistance, due to increased efflux 
pumps such as P-glycoprotein (Pgp) in the 
cell membrane, which transport most of 
anticancer drugs out of the cell, is also major 
problem. (20, 21) Thus, there is a need to 
develop such a delivery system, which 
combines safety, efficacy, and convenience. 
The lack of efficient treatment has created the 
need to develop and implement novel 
technology based on combination strategy of 
cyclodextrin complexation and 
nanotechnology with a view to make the 
therapy more useful and acceptable. 
The formation of inclusion complex with 
nontoxic agents leads to improvement in 
physicochemical properties of drug. (22-27) 
Complexation of doxorubicin with 𝛾-CD and 
HP-𝛾-CD led to an increase in permeability 
across blood brain barrier, due to the 
disruption of the membrane. (28) Similarly, 
the 𝛽-CD-PEG folic acid conjugate increased 
the solubility of chlorambucil. Complexation 
of  9- nitro camptothecin with HP-𝛽-CD led 
to significant enhancement in antitumor 
activity with low toxicity. (29) 
3. Drug in Cyclodexrtin in Liposome” as a 
drug delivery carrier  
“Liposomes can encapsulate hydrophilic as 
well as hydrophobic drug in its aqueous core 
and lipid bilayer respectively. Additionally, 
their composition can be adapted to achieve 
predetermined release and circulation in 
biological environment. In comparison with 
ICs, liposomes can encapsulate and retain 
drug molecule with better stability profile, 
has long circulation time when PEGylated 
and are able to deliver drug pay load to the 
specific sites.  But, it is observed that the 
amount of drug loaded in the bilayer is 
limited and is determined by the drug to lipid 
molar ratio which is generally low. Further, 
lipophilic drugs incorporated in higher 
amount in bilayer may destabilize the 
membrane thus impacting formation of stable 
bilayer thus releasing the content 
prematurely. (30, 31) 
CD and liposomes have been extensively 
explored as carrier containers to deliver drugs 
efficiently. However, they differ in their 
structural properties, drug encapsulation and 
retention efficiencies and in vivo behavior. 
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Figure 1. Types of Cyclodextrins 
The novel concept, would allow 
entrapment of water soluble cyclodextrin ICs 
of water insoluble drugs such as PTX in 
aqueous core of liposomes. The extent of 
loading efficiency depends on the entrapment 
of drug into CD cavity, the concentration of 
ICs in solution during liposomal formulation 
and the method of preparation of liposomes. 
This strategy has been explored by some of 
the researches to encapsulate water insoluble 
drugs in aqueous compartment of liposomes 
and seems to be promising in improving drug 
to lipid molar ratio and loading efficiency as 
compared to conventional incorporation of 
drugs in lipid phase. (32-35) herein, a suitable 
alternative is to encapsulate drug as CD 
complex in the aqueous core. Incorporation of 
lipophilic drug in form of water soluble 
complex only in core though improves the 
stability of the system but present limitation 
in the amount being loaded as the volume of 
aqueous compartment is very low compared 
to the volume of bilayer. Such strategy has 
been widely used to accommodate a variety 
of lipophilic drug and has shown improved 
physicochemical and pharmaceutical 
properties compared to the conventional 
liposomes.  
4. Cyclodextrin-Based Nanocarriers of 
Anticancer Drugs 
The use of pharmaceutical carriers 
provides a loom, which is more time and 
cost-effective than new drug development. 
(26) 
Cellular/molecular biology has contributed to 
advancement in chemotherapy and gene 
therapy of cancer, optimistically avoiding the 
toxic doses of nonspecific agents. The 
development of new delivery system or new 
administration schedules offer less expensive, 
but more effective treatment with 
negligible/rare side effects. (11-13) 
Progress in nanotechnology and 
Nanoparticles with the size of about 100-
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10,000 times smaller than human cells offer 
unique interaction with biomolecules, which 
may revolutionize cancer diagnosis and 
treatment. They have engorged surface area-
volume ratio and can overcome both cellular 
and noncellular mechanisms of resistance, 
thereby increasing selectivity of drug towards 
cancer cell and reducing toxicity towards 
normal tissues. (9,11,36-38) 
 
Table 2. Examples of Cyclodextrin-enhanced solubility and dissolution 
Improvements Drug 
β-cyclodextrin Nimesulide, sulfomethiazole, lorazepam, 
Ketoprofen, Griseofulvin, ibuprofen 
α-cyclodextrin Praziquantel 
γ-cyclodextrin Omeprazole, digoxin 
HP-β-cyclodextrin Albendazole, Ketoprofen, Itraconazole, Carbamazepine, 
Phenytoin, Rutin 
DM-β-cyclodextrin Naproxen, Campotothesin 
SBE--β-cyclodextrin Danazol, Fluasterone, Spironolactone 






Cyclodextrins are water soluble 
macromolecules made by protein degradation 
of starch which are biocompatible in nature 
with hydrophilic outer surface and lipophilic 
cavity. Due to this feature, CDs form 
inclusion complexes with a wide variety of 
hydrophobic compounds and change the 
physicochemical and biological properties of 
guest molecules. Cyclodextrin consists of (α-
1,4)-linked α-D-glucopyranose unit with a 
lipophilic central cavity and the structures of 
various CDs. CD extensively explored as 
carrier containers to deliver drugs efficiently. 
However, the applications of cyclodextrin in 
clinical setting are yet to be proven for cancer 
therapeutics. 
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